Reply to E.J. Lehrer et al and J.B. De Vis et al.

Autor: Nadal E; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain., Vilariño N; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain., Simó M; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain., Navarro V; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain., Bruna J; Ernest Nadal, MD, PhD, and Noelia Vilariño, MD, Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; Marta Simó, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain; Valentí Navarro, BS, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain; and Jordi Bruna, MD, PhD, Neuro-Oncology Unit, Department of Neurology, Hospital de Bellvitge, L'Hospitalet, Barcelona, Spain.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Mar 01; Vol. 42 (7), pp. 859-861. Date of Electronic Publication: 2023 Dec 11.

Acute toxicology report of the emerging marine biotoxin Brevetoxin 3 in mice: Food safety implications.

Autor: Costas C; Departamento de Farmacología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain., Louzao MC; Departamento de Farmacología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain. Electronic address: mcarmen.louzao@usc.es., Raposo-García S; Departamento de Farmacología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain., Vale C; Departamento de Farmacología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain., Graña A; Departamento de Farmacología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain., Carrera C; Departamento de Farmacología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain., Cifuentes JM; Departamento de Anatomía, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain., Vilariño N; Departamento de Farmacología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain., Vieytes MR; Departamento de Fisiología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain., Botana LM; Departamento de Farmacología, Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain.

Publikováno v: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2023 Dec; Vol. 182, pp. 114178. Date of Electronic Publication: 2023 Nov 08.

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).

Autor: Nadal E; Department of Medical Oncology, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.; Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Rodríguez-Abreu D; Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain., Simó M; Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO, IDIBELL, L'Hospitalet, Barcelona, Spain., Massutí B; Department of Medical Oncology, Hospital General de Alicante, Alicante, Spain., Juan O; Department of Medical Oncology, Hospital Universitari La Fe, Valencia, Spain., Huidobro G; Department of Medical Oncology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain., López R; Department of Medical Oncology, Hospital Clínico de Valladolid, Valladolid, Spain., De Castro J; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain., Estival A; Department of Medical Oncology, Institut Català d'Oncologia (ICO), Badalona, Spain., Mosquera J; Department of Medical Oncology, Hospital Universitario A Coruña, A Coruña, Spain., Sullivan I; Department of Medical Oncology, Hospital Sant Pau, Barcelona, Spain., Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Blasco A; Department of Medical Oncology, Hospital General de Valencia, Valencia, Spain., Guirado M; Department of Medical Oncology, Hospital Universitario de Elche, Elche, Spain., Pereira E; Spanish Lung Cancer Group, Barcelona, Spain., Vilariño N; Department of Medical Oncology, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.; Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO, IDIBELL, L'Hospitalet, Barcelona, Spain., Navarro V; Department of Medical Oncology, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Bruna J; Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO, IDIBELL, L'Hospitalet, Barcelona, Spain.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Oct 01; Vol. 41 (28), pp. 4478-4485. Date of Electronic Publication: 2023 Aug 21.

Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic [Pre-print]

Autor: Vilariño, N, Bruna, J, Nadal, E, Bosch-Barrera, J, Valiente, M, Vilariño, N., Bruna, J., Bosch-Barrera, J., Valiente, M., Nadal, E.

Publikováno v: Repisalud
Instituto de Salud Carlos III (ISCIII)

Brain metastases are frequent complications in patients with non-small-cell lung cancer (NSCLC) associated with significant morbidity and poor prognosis. Our goal is to give a global overlook on clinical efficacy from immune checkpoint inhibitors in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4adfd53e478d35facbdadb65c202822
https://hdl.handle.net/20.500.12105/15049

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.

Autor: Martínez-Bosch N; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Unidad Asociada IIBB-CSIC, 08003 Barcelona, Spain., Vilariño N; Medical Oncology Department, Hospital Duran i Reynals, Catalan Institute of Oncology, L'Hospitalet, 08908 Barcelona, Spain., Alameda F; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Unidad Asociada IIBB-CSIC, 08003 Barcelona, Spain.; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain., Mojal S; Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Institut d'Investigacions Biomèdiques IIB-Sant Pau, 08025 Barcelona, Spain., Arumí-Uria M; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Unidad Asociada IIBB-CSIC, 08003 Barcelona, Spain.; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain., Carrato C; Department of Pathology, Hospital Germans Trias i Pujol, 08916 Badalona, Spain., Aldecoa I; Department of Pathology, Center for Biomedical Diagnosis, Hospital Clinic de Barcelona, University of Barcelona, 08036 Barcelona, Spain.; Neurological Tissue Bank of the Biobank-Hospital Clinic-IDIBAPS (Instituto de Investigaciones Biomédicas August Pi i Sunyer), 08036 Barcelona, Spain., Ribalta T; Department of Pathology, Center for Biomedical Diagnosis, Hospital Clinic de Barcelona, University of Barcelona, 08036 Barcelona, Spain., Vidal N; Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet, 08907 Barcelona, Spain., Bellosillo B; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Unidad Asociada IIBB-CSIC, 08003 Barcelona, Spain.; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain., Menéndez S; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Unidad Asociada IIBB-CSIC, 08003 Barcelona, Spain., Del Barco S; Medical Oncology, Institut Catala d'Oncologia (ICO) Girona, Hospital Josep Trueta, 17007 Girona, Spain., Gallego O; Department of Medical Oncology, Hospital de Sant Pau, 08036 Barcelona, Spain., Pineda E; Department of Medical Oncology, Hospital Clínic Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain., López-Martos R; Department of Pathology, Hospital Germans Trias i Pujol, 08916 Badalona, Spain., Hernández A; Badalona Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Institut Catalá d'Oncologia (ICO), 08916 Badalona, Spain., Mesia C; Neuro-Oncology Unit and Medical Oncology Department, Institut Catala d'Oncologia (ICO), Institut de Investigació Bellvitge (IDIBELL), L'Hospitalet, 08908 Barcelona, Spain., Esteve-Codina A; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain., de la Iglesia N; IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain., Balañá C; Badalona Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Institut Catalá d'Oncologia (ICO), 08916 Badalona, Spain., Martínez-García M; Department of Medical Oncology, Hospital del Mar, 08003 Barcelona, Spain.; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain., Navarro P; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Unidad Asociada IIBB-CSIC, 08003 Barcelona, Spain.; Departamento de Muerte y Proliferación Celular, Instituto de Investigaciones Biomédicas de Barcelona-Centro Superior de Investigaciones Científicas (IIBB-CSIC), 08036 Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), 08036 Barcelona, Spain.

Publikováno v: Cells [Cells] 2023 Mar 08; Vol. 12 (6). Date of Electronic Publication: 2023 Mar 08.